MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction

Henrik S Thomsen, Peter Marckmann

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Until recently it was believed that extracellular gadolinium based contrast agents (Gd-CA) were safe for both the kidneys and all other organs within the dose range up to 0.3mmol/kg body weight. However, in 2006, it was demonstrated that some Gd-CA may trig the development of nephrogenic systemic fibrosis, a generalized fibrotic disorder, in renal failure patients. This sub-section of European Journal of Radiology covers the current knowledge about NSF from many aspects. The prevention of NSF must be given high priority, but it should not lead to a denial of a well-justified, enhanced MRI examination with a stable agent.
Original languageEnglish
JournalEuropean Journal of Radiology
Volume66
Issue number2
Pages (from-to)153-159
Number of pages6
ISSN0720-048X
DOIs
Publication statusPublished - 1. May 2008

Fingerprint

Gadolinium
Human Body
Contrast Media
Nephrogenic Fibrosing Dermopathy
Radiology
Kidney

Cite this

@article{988bdf50428511dd9fbe000ea68e967b,
title = "MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction",
abstract = "Until recently it was believed that extracellular gadolinium based contrast agents (Gd-CA) were safe for both the kidneys and all other organs within the dose range up to 0.3mmol/kg body weight. However, in 2006, it was demonstrated that some Gd-CA may trig the development of nephrogenic systemic fibrosis, a generalized fibrotic disorder, in renal failure patients. This sub-section of European Journal of Radiology covers the current knowledge about NSF from many aspects. The prevention of NSF must be given high priority, but it should not lead to a denial of a well-justified, enhanced MRI examination with a stable agent.",
author = "Thomsen, {Henrik S} and Peter Marckmann",
year = "2008",
month = "5",
day = "1",
doi = "10.1016/j.ejrad.2008.01.022",
language = "English",
volume = "66",
pages = "153--159",
journal = "European Journal of Radiology",
issn = "0720-048X",
publisher = "Elsevier",
number = "2",

}

MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction. / Thomsen, Henrik S; Marckmann, Peter.

In: European Journal of Radiology, Vol. 66, No. 2, 01.05.2008, p. 153-159.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction

AU - Thomsen, Henrik S

AU - Marckmann, Peter

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Until recently it was believed that extracellular gadolinium based contrast agents (Gd-CA) were safe for both the kidneys and all other organs within the dose range up to 0.3mmol/kg body weight. However, in 2006, it was demonstrated that some Gd-CA may trig the development of nephrogenic systemic fibrosis, a generalized fibrotic disorder, in renal failure patients. This sub-section of European Journal of Radiology covers the current knowledge about NSF from many aspects. The prevention of NSF must be given high priority, but it should not lead to a denial of a well-justified, enhanced MRI examination with a stable agent.

AB - Until recently it was believed that extracellular gadolinium based contrast agents (Gd-CA) were safe for both the kidneys and all other organs within the dose range up to 0.3mmol/kg body weight. However, in 2006, it was demonstrated that some Gd-CA may trig the development of nephrogenic systemic fibrosis, a generalized fibrotic disorder, in renal failure patients. This sub-section of European Journal of Radiology covers the current knowledge about NSF from many aspects. The prevention of NSF must be given high priority, but it should not lead to a denial of a well-justified, enhanced MRI examination with a stable agent.

U2 - 10.1016/j.ejrad.2008.01.022

DO - 10.1016/j.ejrad.2008.01.022

M3 - Journal article

VL - 66

SP - 153

EP - 159

JO - European Journal of Radiology

JF - European Journal of Radiology

SN - 0720-048X

IS - 2

ER -